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Abstract
Background: Trichomonas vaginalis has been associated with increased vaginal HIV-1 RNA shedding in
antiretroviral therapy (ART)-naïve women. The effect of trichomoniasis on vaginal HIV-1 shedding in ART-treated
women has not been characterized. We tested the hypothesis that T. vaginalis infection would increase vaginal
HIV-1 RNA shedding in women on ART, and that successful treatment would reduce vaginal HIV-1 RNA levels.
Methods: We conducted a prospective cohort study including monthly follow-up of 147 women receiving ART in
Mombasa, Kenya. Those with T. vaginalis infection, defined by the presence of motile trichomonads on vaginal
saline wet mount, received treatment with single dose metronidazole (2 g). Test of cure was performed at the next
monthly visit. Using the pre-infection visit as the reference category, we compared detection of vaginal HIV-1 RNA
before versus during and after infection using generalized estimating equations. A cut-off of 100 HIV-1 RNA copies/
swab was used as the lower limit for linear quantitation.
Results: Among 31 women treated for trichomoniasis, the concentration of vaginal HIV-1 RNA was above the limit
for quantitation before, during, and after T. vaginalis infection in 4 (13% [95% CI 4% - 30%]), 4 (13% [95% CI 4% -
30%]), and 5 (16% [95% confidence interval {CI} 5% - 34%]) women respectively. After adjusting for potential
confounding factors, we could detect no difference in the likelihood of detecting vaginal HIV-1 RNA before versus
during infection (odds ratio [OR] 1.41, 95% CI 0.23 - 8.79, p = 0.7). In addition, detection of HIV-1 RNA was similar
before infection versus after successful treatment (OR 0.68, 95% CI (0.13 - 3.45), p = 0.6).
Conclusion: Detection of vaginal HIV-1 RNA during ART was uncommon at visits before, during and after
T. vaginalis infection.
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Background
In sub-Saharan Africa, transmission of HIV-1 is predomi-
nantly heterosexual [1]. The risk of transmission is likely
related to the concentration of virus in genital mucosal
secretions, suggesting that reducing genital HIV-1 shed-
ding may reduce infectivity in seropositive individuals
[2,3]. Clinical studies provide strong evidence that antire-
troviral therapy (ART) leads to rapid and sustained sup-
pression of genital HIV-1 shedding [3,4]. However, this
suppression is incomplete [4,5], and persistent genital
HIV-1 replication may reflect ongoing risk of transmitting
the virus even in individuals on treatment [3].
Trichomonas vaginalis infection is highly prevalent in
many parts of the world. Among HIV-1 positive indivi-
duals, infection with T. vaginalis is associated with higher
genital HIV-1 levels [6,7]. Successful treatment of tricho-
moniasis reduces genital HIV-1 levels in antiretroviral-
naïve women [7] and men [6,8]. Antiretroviral therapy
decreases genital shedding of HIV-1, but there is some evi-
dence that shedding may still be increased in the presence
of genital tract infections. For example, a study in HIV-1
seropositive men on ART demonstrated that gonococcal
urethritis may activate local genital HIV-1 replication [9].
It is not known whether vaginal trichomoniasis
increases HIV-1 shedding in women on ART, or whether
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decrease HIV-1 shedding, potentially decreasing infectiv-
ity [10]. To address these questions, we prospectively
evaluated the effect of T. vaginalis infection on genital
HIV-1 shedding in women on ART.
Methods
Participants
This study was conducted between March 2004 and
December 2008 among HIV-1-seropositive women
between 18 and 45 years old in Mombasa, Kenya. The par-
ticipants were recruited from within a larger cohort of
female sex workers in Mombasa [11]. Women eligible for
ART initiated a first-line regimen of stavudine or zidovu-
dine, lamivudine, and nevirapine, as recommended by the
World Health Organization (WHO) and the Kenyan Min-
istry of Health Guidelines at the time [12]. All participants
gave written informed consent. The study was approved
by the ethical review committees of the Kenya Medical
Research Institute, the University of Washington, and the
Fred Hutchinson Cancer Research Center.
Clinic procedures
Participants in the ART cohort were asked to return for
monthly follow-up visits. During each visit, study nurses
completed a standardized interview covering medical,
gynecological, and sexual history. The study physician per-
formed a general physical examination and pelvic specu-
lum examination with collection of specimens for
laboratory diagnosis of genital tract infections. A Dacron
swab was used to collect vaginal secretions for HIV-1
RNA quantitation by placing the swab firmly on the vagi-
n a lw a l la n dr o l l i n g3t i m e sb e t w e e nt h ef i n g e r t i p s .T h e
swab was then placed into a cryovial with freezing medium
(70% RPMI, 20% fetal calf serum, and 10% dimethyl sulf-
oxide with added penicillin, streptomycin, and amphoteri-
cin B). Genital samples collected for HIV-1 RNA viral load
were stored at -70°C until they were shipped on dry ice to
the Fred Hutchinson Cancer Research Center in Seattle
for testing. Blood samples were collected every three
months for CD4 lymphocyte count.
Treatment of vaginal infections
Women with symptomatic vaginal conditions (vaginal
discharge, itching, or burning) at an examination visit
were treated syndromically according to WHO and Ken-
yan Ministry of Health Guidelines (oral metronidazole 2
g as a single dose combined with clotrimazole 100 mg
intravaginal pessaries nightly at bedtime for 7 nights)
[13]. All genital specimens were obtained prior to provi-
sion of treatment. Patients were asked to return one
week after each examination visit for laboratory results.
At the results visit, additional treatment was provided if
indicated based upon laboratory findings. Those with
T. vaginalis infection received treatment with single dose
oral metronidazole (2 g) only if metronidazole was not
dispensed at the examination visit. Samples collected one
month post-treatment were used to confirm cure.
Women with persistent T. vaginalis infection were
retreated, and then re-evaluated at the next monthly visit.
Participants whose T. vaginalis infection resolved after
treatment (including retreatment) were included in this
study.
Laboratory methods
HIV-1 serostatus was determined by ELISA (Detect HIV1/
2, BioChem Immunosystems, Montreal, Canada). Positive
tests were confirmed using a second ELISA (Recombigen,
Cambridge Biotech, Worcester, Massachusetts, USA).
Quantitation of CD4 lymphocytes was performed using a
manual system (Cytosphere, Coulter, Hialeah, Florida,
USA) from March 2004 until October 2004, and thereafter
by an automated method (FACS Count, Becton Dickinson,
Forest Lakes, New Jersey, USA). HIV-1 RNA quantitation
was performed using a Gen-Probe viral load assay on vagi-
nal samples (Gen-Probe, San Diego, California, USA) [14].
Vaginal saline wet mounts were examined microscopi-
cally at 40X power for the presence of motile T. vaginalis
parasites and yeast cells or hyphae. Vaginal Gram-stained
slides were evaluated for bacterial vaginosis (BV) using
Nugent’s criteria [15]. Bacterial vaginosis was defined as a
Nugent’s score of 7-10. Culture for Neisseria gonorrhoeae
was performed on modified Thayer-Martin media (Difco
BD Diagnostics, Oxford, UK). Endocervical samples were
also tested for the presence of N. gonorrhoeae and Chla-
mydia trachomatis by transcription mediated amplification
using the Aptima GC/CT Detection System (Gen-Probe,
San Diego, California, USA). The presence of sperm in the
genital tract was determined by microscopic examination
of Gram stained slides of cervical and vaginal secretions.
Statistical analysis
Visits before, during and after successful treatment of
T. vaginalis infection were included in this analysis.
Women with concurrent cervical infections were excluded
because previous studies demonstrate that cervical infec-
tions may influence cervicovaginal HIV-1 shedding
[16,17]. We also excluded episodes in which co-infection
with both yeast and T. vaginalis were present. Cases with
concurrent BV were not excluded, as BV commonly coex-
ists with T. vaginalis, and our prior prospective studies
have not shown a decrease in HIV-1 RNA shedding when
women are treated for BV [7]. For this analysis, only trea-
ted episodes of T. vaginalis infection that were followed by
a visit with cure were included. For women with more
than 1 consecutive visit with T. vaginalis infection, only
the first visit with trichomoniasis was included in the
analysis.
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Page 2 of 6Our ap r i o r isample size calculation was based on the
assumption that the majority of women with a genital
infection would have quantifiable genital HIV-1 RNA
levels. Based on this assumption, 31 cases would allow
90% power to detect a 0.6 log10 copies/swab difference in
vaginal HIV-1 RNA levels using a two-sided hypothesis
test at a = 0.05. We have observed reductions in vaginal
HIV-1 RNA greater than 0.6 log10 copies/swab with suc-
cessful treatment of T. vaginalis in studies of ART-naïve
women [7].
The lower limit for linear quantitation for this assay
was 100 copies/ml, which corresponds to 100 copies/
swab (swabs were placed in 1 ml of freezing media).
Because the majority of vaginal HIV-1 RNA levels were
below 100 copies/ml even at the time of T. vaginalis
infection, we followed our pre-specified alternative analy-
sis plan, which dichotomized the outcome (vaginal HIV-
1 RNA) as detectable versus undetectable (< 100 copies/
ml). Analyses were performed using SPSS 13.0 (SPSS
Inc., Chicago, Illinois, USA) and STATA 9 (StataCorp,
College Station, Texas, USA). The primary analysis uti-
lized logistic regression with generalized estimating equa-
tions with an exchangeable correlation matrix to
compare the presence of detectable HIV-1 RNA in vagi-
nal secretions across the three visits, using the pre-infec-
tion visit as the baseline.
Our analysis plan included adjustment for number of
months since ART initiation in all models, because
increasing duration since ART initiation would be
expected to be associated with greater levels of viral sup-
pression, particularly during the first six months of treat-
ment. We then considered adjustment for other potential
confounding factors. Adjustment variables considered
were adherence to ART (measured by visual analogue
scale [VAS], pill count, or pharmacy refill timing),
hormonal contraceptive use (use of oral contraceptives,
Norplant or depot medroxyprogesterone acetate), pre-
sence of concurrent BV, vaginal washing (none, water
only, water and soap), and week of the menstrual cycle
(week 1-3, week 4 and 5, amenorrheic). We used two
approaches to limit the number of potential confounding
factors to include in the final model. First, we assessed
the change across the three visits for each potential con-
founding variable, and second, we assessed the associa-
tion between each variable and the outcome. In the final
adjusted model, we only included variables that differed
significantly across the three visits or were significantly
related to the outcome (p = 0.1).
Results
Between March 2004 and December 2008, 147 women
enrolled in the ART cohort. Of these, 41 acquired
T. vaginalis infection (incidence, 5.8 per 100 person-
years). Ten women were excluded from these analyses.
Three did not receive treatment for T. vaginalis infec-
tion in our clinic because they did not return for results.
These women were found to have no T. vaginalis pre-
sent at later examinations. Two women had concurrent
cervical infections, and two were lost to follow-up. We
also excluded three women who were missing vaginal
HIV-1 RNA data (2 at the pre-infection visit and 1 at
the infection visit). Thirty-one women were included in
the final analysis (Table 1). Their median age was 36
years (interquartile range [IQR] 31 - 38). At ART initia-
tion, the majority were classified as WHO stage 3 or 4
(65%). The median time from ART initiation to the pre-
trichomoniasis visit was 10.3 months, IQR (3.6-19.0).
Thirty (97%) women remained on first-line ART at the
time of their first visit contributing to this analysis,
while one woman had changed to a second-line regimen
consisting of didanosine, zidovudine, and lopinavir/rito-
navir 7 months prior to her infection episode.
The number of women with detectable vaginal HIV-1
RNA before, during, and after T. vaginalis infection was 4
(13% [95% confidence interval {CI} 4% - 30%]), 4 (13%
[95% CI 4% - 30%]), and 5 (16% [95% CI 5% - 34%]),
respectively. For women with detectable vaginal HIV-1
RNA, the median HIV-1 RNA levels before, during, and
after T. vaginalis infection were 1438 (range 100 - 7223)
copies/swab, 451 (range 105 - 928) copies/swab and 770
(range 105 - 29675) copies/swab respectively. Of the eight
women with detectable vaginal HIV-1 RNA, one woman
had detectable HIV-1 RNA at all three visits, three had
detectable HIV-1 RNA at two visits and the other four
had detectable HIV-1 RNA at only one visit.
Compared to the pre-infection visit, we were unable to
detect differences in genital HIV-1 RNA either during
infection (p = 0.96) or following successful treatment (p =
0.81; Table 2). The results were similar after adjusting for
potential confounding factors, in sensitivity analyses
excluding 5 visits where sperm was detected in genital
secretions, and in analyses excluding the participant on
second-line ART (data not shown).
Discussion
Longitudinal sample collection in this study allowed us to
compare genital HIV-1 shedding before, during, and after
T. vaginalis infection. Among women receiving ART, we
could detect no differences in HIV-1 RNA before versus
during T. vaginalis infection. In addition, we were unable
to detect differences in HIV-1 RNA after treatment of
vaginal trichomoniasis in this population. Two thirds of
the women in this study had undetectable genital HIV-1
shedding before, during, and after an episode of
trichomoniasis.
In light of increasing global interest in the secondary
HIV-1 prevention benefits of ART [18], it is important to
understand whether factors suspected of increasing
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treated individuals, and thus may be likely to contribute to
increased risk of transmission by those receiving treat-
ment. Prior studies have demonstrated that sexually trans-
mitted infections (STIs) are associated with higher genital
HIV-1 viral loads in women [7,16,17,19]. However, few
studies have examined the effect of STIs or their treatment
on genital HIV-1 shedding among women taking ART.
Kissinger et al. examined the effect of treating T. vaginalis
infection on vaginal HIV-1 RNA among ART-naïve and
ART-treated HIV-1 positive women [20]. They found that
treatment of trichomoniasis was associated with a signifi-
cant reduction in HIV-1 RNA at 3 months post treatment
(odds ratio 0.34, 95% CI 0.12-0.92; p = 0.03). In addition,
compared to women not taking ART, women taking ART
were less likely to have vaginal HIV-1 RNA shedding
(odds ratio 0.25, 95% CI 0.10-0.62, p = 0.01) Based on a
prior study of genital HIV-1 shedding in the setting of
treatment for T. vaginalis in ART-naïve women [7], it is
possible that the significant reduction in HIV-1 RNA
detection after trichomoniasis treatment observed by Kis-
singer et al. was driven by the participants who were not
taking ART (45%). The study by Kissinger and colleagues
d i dn o tp r e s e n tr e s u l t sf o rt h eA R T - t r e a t e ds u b s e to f
women separately, so it was not possible to directly com-
pare with our findings. Our present results demonstrate
that ART can maintain vaginal HIV-1 suppression in the
majority of women even when T. vaginalis infection is
present.
The results presented here parallel those from recently
published data from the same cohort assessing the impact
of cervical infections [21] and genital ulcer disease (GUD)
on genital HIV-1 shedding [22]. In the cervicitis study,
HIV-1 RNA was detected in cervical secretions of 30
women before, during, and after cervicitis at one (3.2%),
five (16.1%), and three (9.7%) visits, respectively. In the
GUD study of 36 women, HIV-1 RNA was detected
before, during and after GUD in cervical secretions from
four (11%), one (3%) and six (17%) women, respectively,
and in vaginal secretions from three (8%), four (11%) and
four (11%) women, respectively. Our present findings add
to an expanding evidence base showing that ART gener-
ally maintains low or undetectable genital HIV-1 levels
even in the presence of STIs.
There were limitations to this study. The sample size
was initially calculated based on an assumption that more
than half of women would have detectable genital HIV-1
RNA, which would have permitted us to compare the
average HIV-1 RNA concentrations at different time
points. Since most women actually had undetectable
Table 1 Baseline characteristics of the 31 participants at
the pre-infection visit
Characteristic Median (IQR) or Number
(percent)
Demographics
Age (years) 36 (31 - 38)
Education (years) 7 (7 - 8)
Pregnant 1 (3.2)
Hormonal contraceptive method 7 (22.6)
OCP 1 (3.2)
DMPA 4 (12.9)
Norplant 2 (6.5)
Risk Behavior
Number of partners in the last
week
0( 0-1 )
Frequency of intercourse in the
last week
0( 0-2 )
Percent condom use in the last
week
a
100 (75 - 100)
Clinical
WHO HIV staging at ART initiation
Stage I 3 (9.7)
Stage II 8 (25.8)
Stage III 17 (54.8)
Stage IV 3 (9.7)
CD4 lymphocyte count (cells/ml)
At start of antiretroviral therapy 126 (68 - 159)
Pre-infection visit
b 241 (161 - 292)
On stavudine, lamivudine, and
nevirapine
c
30 (96.7)
Time since ART initiation (months) 10.3 (3.6 - 19.0)
ART adherence in the past month
On-time refills
d 27 (87.1)
Pill count adherence ≥ 95% 21 (67.7)
IQR, interquartile range.
a Among 15 women who reported sexual intercourse in the last week.
b CD4 count at the pre-infection visit or nearest visit prior to infection was
used.
c One woman was on a second-line regimen consisting of lopinavir/ritonavir,
didanosine, and zidovudine.
d Late refills were defined as occurring > 48 hours after a refill was due.
Table 2 Vaginal HIV-1 RNA detection before, during, and after vaginal trichomoniasis in 31 women
Visit N (%) aOR
a (95% CI) P-value aOR
b (95% CI) P-value
Pre-infection visit 4 (13%) 1.0 (ref) 1.0 (ref)
Infection visit 4 (13%) 0.97 (0.30 - 3.12) P = 0.96 1.41 (0.23 - 8.79) P = 0.71
Post-infection visit 5 (16%) 1.19 (0.28 - 5.05) P = 0.81 0.68 (0.13 - 3.45) P = 0.64
aOR, adjusted odds ratio; 95% CI, 95% confidence interval.
a Adjusted for duration on ART.
b Adjusted for BV, late refill, hormonal contraception (yes/no), week of menstrual cycle and duration on ART.
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based on the presence or absence of vaginal HIV-1 RNA
above the threshold for linear quantitation. While this lim-
ited the power of our analyses, the results remain useful,
as they demonstrate that there were not large increases in
either detection or quantity of vaginal HIV-1 RNA asso-
ciated with episodes of T. vaginalis infection. A post hoc
power calculation shows that with a sample size of 31,
we had 80% power to detect a 5-fold increase in genital
HIV-1 RNA detection with T. vaginalis infection. A sec-
ond limitation is that the diagnosis of trichomoniasis by
wet mount has limited sensitivity as it relies on visualiza-
tion of motile protozoa. Because this method is relatively
inexpensive, it is still highly relevant in resource-
constrained settings such as our study site. A third limita-
tion was the choice to measure only vaginal viral loads.
In an earlier study of ART-n a ï v ew o m e n ,w ef o u n dt h a t
vaginal HIV-1 RNA levels decrease after treatment of
T. vaginalis infection [7]. Our objective in the present
study was to determine if the effect was the same in ART-
treated women. Although vaginal secretions are probably
the most relevant sample type for a study of genital HIV-1
shedding and T. vaginalis infection, we acknowledge that
we cannot rule out increases in cervical HIV-1 shedding in
women with trichomoniasis. An additional limitation is
that these data may not be generalizable to women on
other ART regimens. This is particularly relevant in the
case of protease inhibitors, which have lower penetration
of the genital tract compared to non-nucleoside reverse-
transcriptase inhibitors (NNRTIs). However, because
NNRTIs are extensively prescribed in first-line regimens
throughout the world [12], our findings should have broad
applicability.
Conclusion
In conclusion, we found that detection of vaginal HIV-1
RNA during ART was uncommon at visits before, during
and after T. vaginalis infection. These findings suggest
that the powerful effect of ART on genital HIV-1 shedding
may lessen the potentiating effects of vaginal infections on
HIV-1 transmission risk.
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